Not independent
Tenure on this board
1.4 yrs
Meeting calendar
KMTS · Annual meeting · Wednesday, September 9, 2026
Kestra Medical Technologies Ltd
3 nominees · 2 ballot items.
Elect three Class II directors (Traci S. Umberger, Raymond W. Cohen, and Kevin Reilly) to serve until the 2029 annual meeting, and ratify PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2027.
Market cap
$1.3B
1Y TSR
+54.2%
Board grade
C-
Record date
Jul 17, 2026
Filing
DEF 14A
Filed Jul 28, 2026 · DEF 14A
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect Traci S. Umberger, Raymond W. Cohen, and Kevin Reilly as Class II directors to serve until the 2029 annual meeting of shareholders and until their successors are duly elected and qualified.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2027.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
1.4 yrs
Also a director at
Rxsight Inc (RXST)
Independent
Tenure on this board
1.4 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAIN CAPITAL INVESTORS LLC | 43.0% | 25,172,338 | $502M |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 10.1% | 5,928,573 | $118M |
| 3 | FMR LLC | 8.3% | 4,843,881 | $97M |
| 4 | Andera Partners | 4.6% | 2,695,192 | $54M |
| 5 | Yu Fan | 3.9% | 2,282,519 | $45M |
| 6 | BROWN ADVISORY INC | 2.8% | 1,637,324 | $33M |
| 7 | EVENTIDE ASSET MANAGEMENT, LLC | 2.5% | 1,445,864 | $29M |
| 8 | ALLIANCEBERNSTEIN L.P. | 2.3% | 1,320,374 | $35M |
| 9 | FRANKLIN RESOURCES INC | 2.1% | 1,218,961 | $24M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 1,212,693 | $24M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Kestra Medical Technologies Ltd’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.5B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$740M
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$371M
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.5B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Reference
Frequently asked questions
- When is the Kestra Medical Technologies Ltd 2026 annual meeting?
- Kestra Medical Technologies Ltd (KMTS) holds its 2026 annual shareholder meeting on Wednesday, September 9, 2026.
- What is the record date for the Kestra Medical Technologies Ltd 2026 meeting?
- The record date for the Kestra Medical Technologies Ltd 2026 meeting is Friday, July 17, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Kestra Medical Technologies Ltd's 2026 meeting?
- The board is presenting 3 director nominees at the Kestra Medical Technologies Ltd 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Kestra Medical Technologies Ltd 2026 meeting?
- Shareholders will vote on 2 proposals at the Kestra Medical Technologies Ltd 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.